Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine-enhanced Buprenorphine for Opioid Dependence
NCT01052662Phase 3Completed
- Sponsor
- University of Massachusetts
- Start
- Oct 2009
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of memantine in opioid use disorder (OUD) (3 arms), sponsored by University of Massachusetts. Primary endpoints: Change of Opioid Use From Week 1 to 13 and Number of Participants Who Were Estimated to Have Survived as Assessed by Survival Curve of Relapse Rate After Achieving Complete Abstinence on Week 8. Started Oct 2009; status: completed.
02
Drugs
memantine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT01052662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01052662.